Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
- K. Ang, Q. Zhang, R. Axelrod
- MedicineJournal of Clinical Oncology
- 20 September 2014
Adding cetuximab to radiation-cisplatin did not improve outcome and hence should not be prescribed routinely, and the PFS and OS were higher in patients with p16-positive OPC, but outcomes did not differ by EGFR expression.
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis.
PCI in stage III NSCLC significantly decreases the risk of BM without improving 1-year OS, and there was a significant decline in memory (HVLT) at 1 year.
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
- F. Robert, M. Ezekiel, H. Waksal
- Medicine, BiologyJournal of Clinical Oncology
- 1 July 2001
The most commonly reported adverse events were fever, asthenia, transaminase elevation, nausea, and skin toxicities (grade 1 to 2 in most patients).
Patterns of surgical care of lung cancer patients.
- A. Little, V. Rusch, A. Stewart
- MedicineAnnals of Thoracic Surgery
- 1 December 2005
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study…
In patients with stage III disease without progression of disease after treatment with surgery and/or radiation therapy with or without chemotherapy, PCI decreased the rate of BM but did not improve OS or DFS.
Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck.
- J. Caudell, P. Schaner, R. Desmond, R. Meredith, S. Spencer, J. Bonner
- MedicineInternational Journal of Radiation Oncology…
- 1 February 2010
Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.
- J. Caudell, P. Schaner, J. Bonner
- MedicineInternational Journal of Radiation Oncology…
- 1 February 2009
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.
- A. Aupérin, C. Le Péchoux, R. Arriagada
- MedicineAnnals of Oncology
- 1 March 2006
Concomitant platin-based radio-chemotherapy may improve survival of patients with locally advanced NSCLC, however, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.
...
...